Sera Prognostics

Sera Prognostics is a private biotechnology company developing diagnostic testing technologies that use proprietary biomarkers to predict preterm birth and other pregnancy complications. The company's tests aim to provide women and their doctors with the ability and time to alter maternal and newborn health through personalized treatment and care plans. Sera Prognostics has completed the landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study, which demonstrated that the PreTRM test can highly predict preterm birth in early pregnancy.